1. Scrip
  2. >>Business
  3. >>Deals

Carlyle Cancels Vectura Auction At Eleventh Hour As Bid Declared Final

Private Equity’s Offer Falls Short Of Rival Philip Morris

 
• By Dean Rudge

Private equity group Carlyle has pulled the plug on a potential auction to take control of the UK-based Vectura group by declaring final its revised bid for the respiratory specialist. Tobacco giant Philip Morris had offered a 10% premium to Carlyle’s bid.  

Philip Morris Logo Magnifying Glass
• Source: Alamy

A proposed auction to take control of the UK-based Vectura Group plc has come swiftly to a halt after one of the company’s bidders, the private equity firm Carlyle, declared its offer final.

Carlyle’s Murano Bidco fund declared it would not raise its 155 pence ($2.15) per share offer for the respiratory specialist, considering it “full and fair,” while taking a swipe at rival bidder Philip Morris International and appealing to Vectura shareholders to “consider the broader context and the impact of each offer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

More from Business